Kentucky 2026 Regular Session

Kentucky House Bill HB263

Introduced
1/8/26  
Refer
1/8/26  

Caption

AN ACT relating to undesignated glucagon.

Impact

The proposed legislation has the potential to significantly impact state laws concerning health and safety regulations in schools. By allowing schools to maintain a supply of undesignated glucagon and designate trained personnel for its administration, the bill reinforces the health management tools available to schools, enhancing the ability to respond to emergency health situations. Moreover, it instills a framework for school health policies regarding diabetes care and establishes clear roles for healthcare practitioners, pharmacists, and educators, ultimately aiming to improve student safety and wellbeing within educational environments.

Summary

House Bill 263 aims to establish regulations regarding the administration of undesignated glucagon in educational settings. This legislation authorizes public, private, and parochial schools to stock and administer glucagon to students experiencing severe hypoglycemia or similar medical issues as outlined in the students' diabetes management plans. Trained individuals within these schools are designated to manage these emergency situations when a licensed healthcare practitioner is unavailable. The bill encourages timely medical response in schools and fosters trained staff's confidence in handling critical health situations involving students with diabetes.

Sentiment

Opinions regarding HB263 are generally favorable, with support emerging primarily from educational organizations and health advocates emphasizing the necessity for swift action during medical emergencies. Proponents argue that the bill is a crucial step towards ensuring the safety of students living with diabetes, eliminating unnecessary delays in care. However, there may be concerns regarding the extent of training and preparedness among school staff, needing careful consideration to avoid potential mishaps in emergency situations.

Contention

Debate around the bill may center on the appropriateness of administering medication by unlicensed personnel, potentially raising questions about accountability and the adequacy of training for school staff. Another point of contention could involve civil liability provisions, which aim to protect individuals administering glucagon in good faith from legal repercussions. Critics might raise concerns about whether such protections could discourage proper training and adherence to best practices when dealing with sensitive health matters involving children.

Companion Bills

No companion bills found.

Previously Filed As

KY HB75

AN ACT relating to undesignated glucagon.

KY HB174

AN ACT relating to undesignated glucagon.

KY HB688

AN ACT relating to health care.

KY SB88

AN ACT relating to physician assistants.

KY HB389

AN ACT relating to prescription drugs.

KY HB305

AN ACT relating to health care.

KY HB658

AN ACT relating to social work.

KY HB571

AN ACT relating to medicinal cannabis.

KY HB414

AN ACT relating to perinatal palliative care.

KY HB95

AN ACT relating to adulterated food.

Similar Bills

KY HB75

AN ACT relating to undesignated glucagon.

KY HB174

AN ACT relating to undesignated glucagon.

NJ A4548

Concerns administration of ready-to-use undesignated glucagon rescue therapy in public schools.

FL S0772

Diabetes Management in Schools

MA H671

Relative to undesignated glucagon rescue therapies in schools

FL H0597

Diabetes Management in Schools

KY HB688

AN ACT relating to health care.

KY HB177

AN ACT relating to health care.